Jerusalem-based Anchiano Therapeutics, a clinical-stage biopharmaceutical company focused on the development of therapies to treat cancer-related diseases, plans to tap the US capital markets.
The biotech’s filing Monday via book-runner Ladenburg Thalmann and Oppenheimer comes with a placeholder size of $35 million.
The company is looking to list its American Depositary Shares on the tech-laden Nasdaq and trade under the ticker symbol ANCN.
It is primarily developing Inodiftagene vixteplasmid for the treatment of non-muscle invasive bladder cancer.
The biotech has offices in Cambridge, Massachusetts and Jerusalem, Israel.
San Francisco-based Alector Inc, a clinical stage biopharmaceutical company, is seeking to raise $150 million, according to a filing submitted to the Securities and Exchange Commission.
Alector is focused on developing therapies to treat neurodegenerative diseases such as dementia.
Alector announced the initiation of a first-in-human Phase 1 trial called the INVOKE study, investigating the company’s second product candidate, AL002, for the treatment of patients with Alzheimer’s disease.
In 2017, Alector entered a global strategic partnership with AbbVie Inc (NYSE:ABBV) that includes the AL002 program.
The biotech reported a net loss of $34.9 million on revenue of $18.5 million as of September 2018.
Alector plans to trade under the ticker symbol ALEC when it lists on the Nasdaq.
Contact Uttara Choudhury at [email protected]
Follow her on Twitter: @UttaraProactive